So I think the talk of #ACR21 has been ORAL Surveillance, the phase 3b/4 @US_FDA post-marketing requirement study of tofacitinib vs TNFi in CV risk pts. I've tried to capture this live through a few threads/tweets, as it happened. Catch up via this thread of threads @RheumNow